Biogen Inc.’s lone surviving patent on multiple-sclerosis drug Tecfidera, which accounted for nearly a third of the company’s revenue last year, was invalidated by a federal judge who said the issue was already decided by another court in June.
U.S. District Judge Maryellen Noreika in Wilmington, Delaware, said Wednesday Biogen could not re-litigate in her court a June 18 ruling by a federal court in West Virginia that found the Tecfidera patent, which expires in February 2028, should never have been issued. An appeals court in Washington has agreed to hear the West Virginia case on an expedited basis ...
